A Phase 1, Open-Label, Q21 Day Dose Escalation, Multi-Center Study of TPI 287 in Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2013
At a glance
- Drugs TPI 287 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Cortice Biosciences
- 19 Dec 2013 Last checked against ClinicalTrials.gov
- 14 Feb 2008 The expected completion date for this trial is now 1 Feb 2007.
- 11 Oct 2007 Status changed from in progress to completed.